New immunotherapy cocktail targets tough colon cancer
NCT ID NCT07253896
First seen Dec 08, 2025 · Last updated Jun 20, 2026 · Updated 38 times
Summary
This phase 2 trial is testing whether adding an immunotherapy drug (AK104) to standard chemotherapy and a targeted therapy (cetuximab or bevacizumab) can shrink tumors in people with a specific type of advanced colorectal cancer (MSS type) that has already been treated once. The study will enroll 40 adults aged 18-75. The main goal is to see how many patients have a significant reduction in tumor size that lasts at least 4 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SAFETY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
the Second Affiliated Hospital of Medical College of Zhejiang University
RECRUITINGHangzhou, Zhejiang, 310000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
the Second Affiliated Hospital of Medical College of Zhejiang University
RECRUITINGHangzhou, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AK104 (a type of immunotherapy) combined with chemotherapy (FOLFIRI) and either cetuximab or bevacizumab
What this could lead to
If successful, this could offer a new second-line treatment option for people with a common type of advanced colorectal cancer that hasn't responded to initial therapy.
What could go wrong
This is an early-phase trial with only 40 participants, so results may not apply broadly. The combination of drugs may cause significant side effects, and the treatment may not shrink tumors as hoped.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.